Maze Therapeutics, Inc.

MAZE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
Operating Activities
Net Income$52,231-$100,415-$114,940
Dep. & Amort.$3,297$4,089$3,820
Deferred Tax$0$0$0
Stock-Based Comp.$9,646$8,747$6,736
Change in WC-$1,523-$6,316-$3,236
Other Non-Cash$12,303$7,068$8,417
Operating Cash Flow$75,954-$86,827-$99,203
Investing Activities
PP&E Inv.-$1,147-$441-$1,966
Net Acquisitions$0$0-$1,204
Inv. Purchases$0$0$0
Inv. Sales/Matur.$0$0$0
Other Inv. Act.$0$0$0
Investing Cash Flow-$1,147-$441-$3,170
Financing Activities
Debt Repay.$24,475$16,176$0
Stock Issued$68,372$209$1,728
Stock Repurch.$0$0$0
Dividends Paid$0$0$0
Other Fin. Act.$0$0$0
Financing Cash Flow$92,847$16,385$1,728
Forex Effect$0$0$0
Net Chg. in Cash$167,654-$70,883-$100,645
Supplemental Information
Beg. Cash$30,246$101,129$201,774
End Cash$197,900$30,246$101,129
Free Cash Flow$74,807-$87,268-$101,169
Maze Therapeutics, Inc. (MAZE) Financial Statements & Key Stats | AlphaPilot